News

Arresto develops medicines that target enzymes involved in the synthesis of the extracellular matrix, which appear to play a role in the etiology of a variety of fibrotic

VistaGen’s initial AV-101 Phase 1 clinical trial was a randomized, double-blind, placebo-controlled study designed to evaluate the safety and pharmacokinetics of single doses of AV-101 in two cohorts

For the study, David Myszka, founder of Biosensor Tools and director of the Center for Biomolecular Interaction Analysis at the University of Utah, used surface plasmon resonance (SPR)

In the first two cohorts of healthy volunteers, the safety, tolerability, pharmacokinetics and optimal formulation of the candidate compound will be evaluated during a placebo controlled dose escalation.

Under the agreement, Oncolys may receive up to $286m as well as upfront, development, regulatory and sales milestone payments. In addition, Oncolys is eligible to receive tiered royalties

Megapharm is EpiCept’s partner in Israel and upon Ministry of Health approval of labeling and other technical matters the company is expected to launch Ceplene in the first

The technology creates transient bonds between larger molecules such as proteins and peptides, including insulin, and a carrier.Ascendis Pharma claims that the TransCon Linker technology has shown promising

Haojishi is an anti-inflammatory analgesic poultice that contains glycol salicylate and menthol as two of its main ingredients. Available in China as a prescription medication, the product comes

The new, 23,000 square meter innovation center, which will provide space for 500 people, is due to be completed by the end of 2012. The new innovation center